maccura(300463)2025-01-23 09:30Financial Performance Forecast - The estimated net profit for 2024 is projected to be between 120 million and 180 million CNY, representing a decline of 42.42% to 61.61% compared to the previous year's profit of 312.62 million CNY[3] - The estimated net profit after deducting non-recurring gains and losses is expected to be between 118 million and 177 million CNY, a decrease of 43.93% to 62.62% from the previous year's figure of 315.66 million CNY[3] - The impact of non-recurring gains and losses on net profit is estimated to be around 2 million CNY, mainly from government subsidies and charitable donations[6] - The financial data in the performance forecast is preliminary and has not been audited by an external accounting firm[4] - Detailed financial data for the 2024 fiscal year will be disclosed in the company's annual report[7] Goodwill Impairment and Market Challenges - The company plans to recognize goodwill impairment in the range of 90 million to 110 million CNY due to lower-than-expected market promotion and sales of digital PCR products[5] - The decline in performance is attributed to intensified industry competition and a decrease in sales revenue from agency products, while self-owned product sales growth has slowed[6] Strategic Focus and Investment - The company is focusing on optimizing channel strategies and accelerating the promotion of intelligent laboratory solutions to enhance market share of self-owned products[6] - Research and development investment has continued to grow year-on-year, supporting the rapid iteration of self-owned products[6] - The company is in the early stages of market promotion for the digital PCR technology acquired from Beijing Dawei Microbiology Technology Co., Ltd[5]